AiCuris Announces Start of LipP 1
First Subject Enrolled in the Clinica Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

more ...


AiCuris Announces U.S. NIH Support of Preclinical Study with AIC649

more ...


AiCuris hosts mini-symposium of experts to discuss challenges and breakthroughs in anti-infectives at BIO-Europe® 2016

more ...


AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on Challenges and Breakthroughs of Anti-infective Therapies at the BIO-Europe® 2016

more ...


AiCuris’ licensee MSD says Letermovir, an investigational prophylactic therapy against HCMV in bone marrow transplant patients, met Primary Endpoint in Pivotal Phase 3 Study

more ...


AiCuris with Case Study in Going Public “Biotechnologie 2016”

more ...


AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study

more ...


Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug

more ...


AiCuris Initiates Clinical Development for Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus

more ...


AiCuris’ AIC649 Shows Potential to Induce Functional Cure of Chronic Hepatitis B in Preclinical Study

AIC649 is an inactivated parapoxvirus ovis (iPPVO) particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses. more ...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
Management Assistant

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com